SCHEMBL2296209

SCHEMBL2296209

Cc1cc(-c2nnc(-c3cc(CC(C)C)c(C)s3)o2)cc(C)c1OCc1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 4/20 0.42
S1PR3 Q99500 3/20 0.42
ALDH1A1 P00352 8/20 0.39
KDM4E B2RXH2 7/20 0.39
LMNA P02545 5/20 0.39
TSHR P16473 4/20 0.39
HSD17B10 Q99714 4/20 0.39
USP2 O75604 1/20 0.39
MYC P01106 1/20 0.38
HPGD P15428 6/20 0.36
SMN1; SMN2 Q16637 6/20 0.36
MAPT P10636 3/20 0.36
BRD4 O60885 1/20 0.35
HTR1D P28221 1/20 0.35
HTR1B P28222 1/20 0.35
BACE1 P56817 1/20 0.35
BACE2 Q9Y5Z0 1/20 0.35
HTT P42858 2/20 0.35
ALOX15 P16050 1/20 0.35
MAPK1 P28482 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL262130 0.88 MYC (0.43) S1PR1S1PR3ALDH1A1KDM4ELMNA
SCHEMBL2294358 0.79 S1PR1 (0.53) S1PR1S1PR3TSHR
SCHEMBL3406367 0.74 S1PR1 (0.41) S1PR1S1PR3ALDH1A1KDM4ELMNA
SCHEMBL2293057 0.74 S1PR1 (0.77) S1PR1S1PR3
SCHEMBL2293060 0.74 S1PR1 (0.77) S1PR1S1PR3
SCHEMBL2294668 0.74 S1PR1 (0.77) S1PR1S1PR3
SCHEMBL2291689 0.73 S1PR1 (0.40) S1PR1S1PR3KDM4ELMNAMAPT
SCHEMBL2545632 0.71 S1PR1 (0.47) S1PR1S1PR3ALDH1A1KDM4ELMNA
SCHEMBL3221506 0.70 TSHR (0.45) S1PR1S1PR3ALDH1A1KDM4ELMNA
SCHEMBL261019 0.70 S1PR1 (0.43) S1PR1S1PR3ALDH1A1KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1976512-B1 NOVEL THIOPHENE DERIVATIVES AS S1P1/EDG1 RECEPTOR AGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2015-09-30 EP disclosed
US-8003800-B2 Thiophene derivatives as S1P1/EDG1 receptor agonists ACTELION PHARMACEUTICALS LTD. (CH) 2011-08-23 US disclosed
US-20100240717-A1 NOVEL THIOPHENE DERIVATIVES AS S1P1/EDG1 RECEPTOR AGONISTS ACTELION PHARMACEUTICALS LTD. (CH) 2010-09-23 US disclosed
EP-1976512-A1 NOVEL THIOPHENE DERIVATIVES AS S1P1/EDG1 RECEPTOR AGONISTS Actelion Pharmaceuticals Ltd. (CH) 2008-10-08 EP disclosed
WO-2007080542-A1 NOVEL THIOPHENE DERIVATIVES AS S1P1/EDG1 RECEPTOR AGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2007-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100240717-A1 NOVEL THIOPHENE DERIVATIVES AS S1P1/EDG1 RECEPTOR AGONISTS S1PR3, S1PR1, S1PR2 S1PR1 2/4885S1PR3 1/4885ALDH1A1 1713/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.